Glioma is the most common tumor in the brain, accounting for 44.69% of intracranial tumors. It is mostly seen in adults, with the most common sites being the frontal, temporal and parietal lobes, but also the brainstem, optic nerve, cerebellum and spinal cord, etc. It is extremely insensitive to treatment. According to the latest statistics, even with the most aggressive treatment (including surgery, radiotherapy and chemotherapy), the two-year survival rates of low-grade astrocytoma, mesenchymal astrocytoma and glioblastoma multiforme are only 66%, 45% and 9%, respectively. Other therapies, including gene therapy, are mostly in the laboratory stage. In most of these tumors, low-grade astrocytomas will transform into higher-grade malignancies, thus greatly reducing survival rates. The role of surgery in the treatment of glioma is well established and its aim is to reduce disability and mortality, maximize the quality of survival and prolong the life of the patient, and a tumor resection level of 95% or more can significantly improve the survival of the patient. We can definitely say that surgery is the most favorable means and tool for the treatment of glioma, but how to achieve tumor resection of more than 95% while protecting brain function is a problem that needs to be seriously considered and studied in our clinic. On the MRIT1 image, the resection of the ring-enhanced area with 2 cm of external discharge can achieve more than 98% resection, but the resection of the ring-enhanced area alone only removes 92% of the tumor, which is not only harmful but also not beneficial. growth up. Therefore, enlarged resection of malignant glioma is beneficial for prolonging the survival of patients. The following issues should be considered when planning the surgery: 1) the surgical technique and experience of the surgeon; 2) the surgical conditions, including anesthesia management, intraoperative electrophysiological monitoring, and ICU monitoring conditions; 3) the possible extent of tumor removal and the overall postoperative treatment plan; 4) the impact of the patient’s other systemic diseases on the surgery; and 5) the impact of surgical trauma on other body systems. The objectives of glioma surgery include: 1) to obtain accurate pathological diagnosis; 2) to remove tumor tissue, eliminate the occupying effect, correct displaced brain tissue and reduce intracranial pressure; 3) to reduce the patient’s neurological symptoms and signs; 4) to remove the absolute majority of tumor cells by “total excision” or near total excision, so as to create conditions for combined treatment such as radiotherapy and chemotherapy. The procedure can be divided into the following categories The surgical approach can be divided into stereotactic tissue biopsy, subtotal resection, and extended resection (invasive surgery, which is more extensive and can include an invasive portion). Many factors can influence the development of a surgical strategy, including the patient’s age, neurological signs and symptoms, available medical conditions, and the diagnosis of other possible diseases. The presence of hydrocephalus, hydrocephalus, tumor size and degree of compression of surrounding tissues, the extent of possible tumor invasion of brain tissue, and the risk of brain herniation are determined based on neuroimaging. Other factors to be considered are whether the patient has received radiotherapy and chemotherapy before surgery, and whether it is a second surgery. The risks of glioma surgery, the possible complications, and the possibility of improving the quality of life and prolonging the survival time of the patient need to be fully considered before surgery. To ensure that a surgery can be successful, the following four points are needed: 1) correct diagnosis; 2) detailed preoperative planning, and the scope of surgical resection must take into account the cognitive function of the brain; 3) skillful surgical technique; 4) perioperative treatment. Obtaining tumor specimens is a guarantee for further implementation of overall therapeutic measures, such as units where immunotherapy has been carried out and tumor cells need to be obtained for tissue culture and vaccine production, which should be given consideration in the development of surgical plans; providing sufficient tumor tissue specimens for conducting molecular pathology and drug sensitivity tests.